Acute coronary syndrome (ACS) Circulatory System Coronary diseases
Conditions
Interventions
Patients are randomized at admission to 80 mg fluvastatin (Lescol XL) or to placebo immediately orally (po) and then once daily for 30 days. Patients are followed up for 360 days.
Sponsors
Novartis Pharma CR s.r.o.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible patients with ST elevation ACS must have resting chest pain less than 12 hours before admission and either >1 mm ST-segment elevation in 2 or more continuous leads or new left bundle branch block on electrocardiogram (ECG). Those with non-ST elevation ACS must have resting chest pain during the previous 48 hours and either >1 mm ST segment depression or negative T waves in 2 or more continuous leads.
Exclusion criteria
Exclusion criteria: Does not match inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Influence of fluvastatin therapy on levels of inflammatory markers (CRP and interleukin-6) and on pregnancy associated plasma protein A (PAPP-A) | — |
Secondary
| Measure | Time frame |
|---|---|
| A combined secondary endpoint is 30-day and one-year occurrence of death, nonfatal myocardial infarction, recurrent symptomatic ischemia, urgent revascularization, and cardiac arrest. | — |
Countries
Czech Republic, Slovakia
Outcome results
None listed